ArticleSubstance abuse and rehabilitation2012
The Treatment Effectiveness Assessment (TEA): an efficient, patient-centered instrument for evaluating progress in recovery from addiction.
Article in Substance abuse and rehabilitation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized, Placebo-Controlled Trial of Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)
Observational Longitudinal Study of Individuals With Stimulant Use Disorder: Research and Development of a Biosignature
Who cites it
28 citing papers in PubMed.
- Quality of life and treatment effectiveness direct and indirect effects on cocaine abstinence outcomes during cocaine use disorder treatment.Drug and alcohol dependence · 2026Trial
- A randomized control trial of a combined community health worker and re-entry intervention for people with HIV recently released from jail who use substances.Journal of substance use and addiction treatment · 2023Trial
- A gender-based secondary analysis of the ADAPT-2 combination naltrexone and bupropion treatment for methamphetamine use disorder trial.Addiction (Abingdon, England) · 2023Trial
- Contingency Management and Pre-Exposure Prophylaxis Adherence Support Services (CoMPASS): A hybrid type 1 effectiveness-implementation study to promote HIV risk reduction among people who inject drugs.Contemporary clinical trials · 2023Trial
- Feasibility and acceptability of electronic administration of patient reported outcomes using mHealth platform in emergency department patients with non-medical opioid use.Addiction science & clinical practice · 2021Trial
- Bupropion and Naltrexone in Methamphetamine Use Disorder.The New England journal of medicine · 2021Trial
- Exercise for methamphetamine dependence: rationale, design, and methodology.Contemporary clinical trials · 2014Trial
- Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use.Journal of psychoactive drugsTrial
- Baseline Moderators of Response to Naltrexone and Bupropion in the Treatment of Methamphetamine Use Disorder: An ADAPT-2 Study.Journal of addiction medicineTrial
- Patient-centered Outcomes in Participants of a Buprenorphine Monthly Depot (BUP-XR) Double-blind, Placebo-controlled, Multicenter, Phase 3 Study.Journal of addiction medicineTrial
- Randomized, placebo-controlled trial of injectable extended-release naltrexone and injectable extended-release buprenorphine for cocaine use disorder (CURB-2): Study rationale and design.Contemporary clinical trials · 2025Article
- Early implementation of an electronic measurement-based care tool in substance use disorder treatment clinics.Journal of substance use and addiction treatment · 2025Article
- Sociodemographic and patient reported outcomes by racial and ethnicity status among participants in a randomized controlled trial for methamphetamine use disorder.Drug and alcohol dependence reports · 2024Article
- Tools to implement measurement-based care (MBC) in the treatment of opioid use disorder (OUD): toward a consensus.Addiction science & clinical practice · 2024Article
- Psychometric properties of the Treatment Effectiveness Assessment in methamphetamine use disorder.Journal of substance use and addiction treatment · 2023Article
- Exploring the performance of during-treatment substance use outcome measures in predicting longer-term psychosocial functioning and post-treatment abstinence.Drug and alcohol dependence · 2023Article
- The phenotype of recovery VII: Delay discounting mediates the relationship between time in recovery and recovery progress.Journal of substance abuse treatment · 2022Article
- The design and conduct of a randomized clinical trial comparing emergency department initiation of sublingual versus a 7-day extended-release injection formulation of buprenorphine for opioid use disorder: Project ED Innovation.Contemporary clinical trials · 2021Article
- Creation of an algorithm for clinical decision support for treatment of opioid use disorder with buprenorphine in primary care.Addiction science & clinical practice · 2021Observational
- A facilitation model for implementing quality improvement practices to enhance outpatient substance use disorder treatment outcomes: a stepped-wedge randomized controlled trial study protocol.Implementation science : IS · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The fields of addiction medicine and addiction research have long sought an efficient yet comprehensive instrument to assess patient progress in treatment and recovery. Traditional tools are expensive, time consuming, complex, and based on topics that clinicians or researchers think are important. Thus, they typically do not provide patient-centered information that is meaningful and relevant to the lives of patients with substance use disorders. To improve our ability to understand patients' progress in treatment from their perspectives, the authors and colleagues developed a patient-oriented assessment instrument that has considerable advantages over existing instruments: brevity, simplicity, ease of administration, orientation to the patient, and cost (none). The resulting Treatment Effectiveness Assessment (TEA) elicits patient responses that help the patient and the clinician quickly gauge patient progress in treatment and in recovery, according to the patients' sense of what is important within four domains established by prior research. Patients provide both numerical responses and representative details on their substance use, health, lifestyle, and community. No software is required for data entry or scoring, and no formal training is required to administer the TEA. This article describes the development of the TEA and the initial phases of its application in clinical practice and in research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.